Sign In
Buy ALT
$2.87
-0.0300 (-1.03%)
At Close: Jun 03, 2026
3 Coronavirus Stocks Poised to Soar in 2021
06:11am, Sunday, 03'rd Jan 2021
They're risky but could deliver huge returns in the new year.
Altimmune (ALT) Begins Phase II Study for Chronic Hepatitis B
10:32am, Thursday, 31'st Dec 2020
Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.
Why These Health Care Stocks Are Moving Today
02:03pm, Wednesday, 30'th Dec 2020
Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B. Altimm
Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B
08:00am, Wednesday, 30'th Dec 2020
GAITHERSBURG, Md., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in its multinatio
Now Could Be the Perfect Time to Buy This Under-the-Radar COVID Vaccine Stock
06:06am, Wednesday, 30'th Dec 2020
It's down, but not out.
Altimmune: AdCOVID's Potential To Prevent Transmission May Be Key To Ending The Pandemic
12:31pm, Tuesday, 29'th Dec 2020
Biotechvalley Insights is upgrading ALT's rating to "Very Bullish" from a "Bullish" rating with a 12 month TP of US$52. Altimmune's (ALT) valuation is at a discount after the recent sell-off, and the
How Big Is This Setback to Altimmune's COVID-19 Vaccine Candidate?
09:40am, Thursday, 24'th Dec 2020
Altimmune Inc. (NASDAQ: ALT) shares dropped on Thursday after the company announced that it had received an update from the U.S.
Clinical hold on COVID-19 vaccine candidate sends Altimmune down 10% (ALT)
08:50am, Thursday, 24'th Dec 2020
Altimmune, a clinical-stage biopharmaceutical company, fell as much as 10% on Thursday after the FDA issued a clinical hold on the company's COVID-19 vaccine candidate. AdCOVID is a single-dose intran
Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial
04:01pm, Wednesday, 23'rd Dec 2020
GAITHERSBURG, Md., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has iss
Why Altimmune Stock Is Soaring Today
10:40am, Monday, 14'th Dec 2020
Investors are excited about an analyst's bullish opinion about the biotech stock.
Altimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference
07:00am, Friday, 11'th Dec 2020
GAITHERSBURG, Md., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer of Altimmun
Altimmune: A COVID-19 Winner After All
11:21pm, Tuesday, 01'st Dec 2020
Share price has recently stumbled due to results of the leading vaccines. Vaccine development timeline is way behind the leading vaccines.
Altimmune (ALT) Files IND for Phase I Study on Coronavirus Vaccine
08:59am, Thursday, 26'th Nov 2020
Altimmune (ALT) files a regulatory application to begin a phase I study in the United States on AdCOVID, its intranasal COVID-19 vaccine candidate. Stock rises.
Simple, single-dose nasal spray offers greater ease and comfort of administration ; positioning AdCOVID as a differentiated vaccine candidate for adults and children
Altimmune to Present at Upcoming Virtual Investor Conferences
07:00am, Monday, 16'th Nov 2020
GAITHERSBURG, Md., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for li
